Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial to evaluate the efficacy and safety of Telomelysin in combination with immune check-point inhibitors

Next Previous
X
Search
Trial Profile

A trial to evaluate the efficacy and safety of Telomelysin in combination with immune check-point inhibitors

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suratadenoturev (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Nov 2023 According to an Oncolys BioPharma media release, U.S. major pharmaceutical company to confirm a basic agreement on the establishment of a joint development system. company will provide Telomelysin, and the U.S. major pharmaceutical company will provide immune checkpoint inhibitors to Cornell University. In addition, the expenses for the clinical trial will be shared equally between the Company and the U.S. major pharmaceutical company. Administration under the clinical trial will begin in 2024.
    • 01 Oct 2016 New trial record
    • 31 Aug 2016 According to an Oncolys BioPharma media release, the company plans to conduct this trial in the US, based on the results of a phase II trial of telomelysin in patients with unresectable or metastatic melanoma (see CTP 700276918).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top